Recurrent Multiple Myeloma

Oncology·MeSH: Multiple Myeloma

Prevalence

17.0 / 100K

Incidence

7.0 / 100K/yr

14 drugs in development·3 companies·7 clinical trials

Drug Pipeline by Phase

Phase 2(10)

Drug	Company
Carfilzomib	FATE THERAPEUTICS INC (FATE)
Carfilzomib	Crinetics Pharmaceuticals, Inc. (CRNX)
Daratumumab and Recombinant Human Hyaluronidase	Crinetics Pharmaceuticals, Inc. (CRNX)
Daratumumab and Recombinant Human Hyaluronidase	FATE THERAPEUTICS INC (FATE)
Pomalidomide	Coeptis Therapeutics Holdings Inc. (COEP)
Pomalidomide	Crinetics Pharmaceuticals, Inc. (CRNX)
Pomalidomide	FATE THERAPEUTICS INC (FATE)
Teclistamab	Crinetics Pharmaceuticals, Inc. (CRNX)
Teclistamab	FATE THERAPEUTICS INC (FATE)
Teclistamab	Coeptis Therapeutics Holdings Inc. (COEP)

Phase 1(4)

Drug	Company
Carfilzomib	Coeptis Therapeutics Holdings Inc. (COEP)
Daratumumab and Recombinant Human Hyaluronidase	Coeptis Therapeutics Holdings Inc. (COEP)
Selvigaltin	FATE THERAPEUTICS INC (FATE)
Selvigaltin	Coeptis Therapeutics Holdings Inc. (COEP)

BioSniper tracks 14 drugs in development for Recurrent Multiple Myeloma across 3 companies.

There are 7 clinical trials targeting Recurrent Multiple Myeloma tracked by BioSniper.

The estimated prevalence of Recurrent Multiple Myeloma is approximately 17.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.